Standard dosage, usage and medication guide for Venetoclax/Venetoclax

1. Drug introduction and mechanism of action

Venetoclax (Venetoclax, also known as venetoclax) is an oral selective BCL-2 inhibitor. BCL-2The protein is a key anti-apoptotic factor in tumor cells. Its high expression can enable cancer cells to escape programmed death, thereby promoting disease progression. Venetoclax selectively binds to BCL-2 protein and inactivates it, thereby restoring the apoptosis mechanism of cancer cells and achieving anti-tumor effects.

Clinically, venetoclax has been widely used in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), acute myeloid leukemia (AML) and other hematological malignancies, especially suitable for patients with relapsed / refractory or with specific molecular mutations. The drug is administered in oral form and is less toxic than traditional chemotherapy. However, it may still cause adverse events such as tumor lysis syndrome (TLS), bone marrow suppression, and gastrointestinal reactions. Therefore, the standard dosage regimen and medication monitoring process must be strictly followed.

2. Standard dosage and dose escalation plan

In order to reduceTLS the risk, venetoclax adopts a "slowly escalating dose" strategy. Take CLL/SLL patients as an example: 1 daily 20 mg, 2 daily 50 mg, 3weeks daily100 mg, 4weeks 200 daily mg, 5 weeks and thereafter daily 400 mgmaintenance. Serum electrolytes, uric acid, creatinine, and liver and kidney function need to be closely monitored during the ramp-up phase.

In AML patients, venetoclax is often given in combination with a hypomethylating drug (azacitidine or decitabine). The recommended starting dose is 100 mg per day, which can be increased to 400 mg or 600 mg according to the combination regimen. The dose adjustment needs to be based on patient tolerance and laboratory indicators. For patients with impaired renal function, abnormal liver function or strong combination useCYP3APatients with inhibitors should appropriately reduce their dose under the guidance of a physician.

3. Medication methods and daily management

Venetoclax is an oral drug and should be taken at the same time every day. It is recommended to take it with or after meals and with plenty of water to reduce gastrointestinal discomfort and stabilize blood concentration.

1.Monitoring in the incremental phase: Before each dose increase, serum potassium, phosphorus, calcium, uric acid and renal function should be tested. The first dose and early increments can be completed in the hospital to ensure timely treatmentTLS.

2.PreventionTLS: Ensure daily 1.5~2 liters of water intake. Allopurinol or rasburicase and other drugs can be used to prevent hyperuricemia according to medical advice.

3.What to do if you miss a dose or stop taking it: If you miss a dose less than 8 hours, you can take it immediately. If it exceeds 8 hours, skip the dose and do not double it at will. Discontinuation or dosage adjustment must be done in accordance with the doctor's advice to avoid affecting the efficacy.

4.Drug interactions: venetoclax CYP3A metabolism, combined with strong inhibitors (ketoconazole, clarithromycin) or inducers (rifampicin, carbamazepine) will significantly affect blood concentration, should be avoided or the dose should be adjusted. Also avoid consuming grapefruit juice.

4. Side Effect Management and Safe Medication

Common side effects of venetoclax include bone marrow suppression (anemia, neutropenia, thrombocytopenia), gastrointestinal reactions (nausea, vomiting, diarrhea), fatigue and abnormal liver function.

1.Myelosuppression: Regular blood routine monitoring is required, and the dose can be adjusted or the drug can be temporarily discontinued if it is mild to moderate. In severe cases, blood transfusion or G-CSF support is required.

2.Gastrointestinal reactions: Taking medication with meals, oral antiemetics, and staying hydrated can reduce nausea and vomiting.

3. Fatigue and abnormal liver function: follow up regularly, rule out other causes, and adjust the dose if necessary.

Rare cases that require attention include pulmonary toxicity, rash, and renal function abnormalities. If symptoms occur, seek medical attention promptly.

5. Treatment course management and drug withdrawal strategies

The length of treatment with Venetoclax varies depending on the type of disease. CLLPatients usually continue taking the drug until 24 months or until disease progression / intolerable toxicity. AMLPatients are often treated with chemotherapy until they achieve remission or are no longer suitable to continue.

Common situations for drug discontinuation or dose reduction include serious adverse reactions (TLS, severe myelosuppression), changes in organ function, or drug interactions. When stopping the drug, you need to follow the doctor's advice to gradually reduce the dose and cooperate with laboratory monitoring. TLSWhen TLS occurs, the drug should be stopped immediately and intensive treatment should be carried out. It can be resumed as appropriate after stabilization.

Reference materials:https://www.drugs.com/